BTIG analyst Ryan Zimmerman raised the firm’s price target on Vericel to $49 from $41 and keeps a Buy rating on the shares. The firm is positive on the company’s “tremendous profitability profile” given that it is a small-cap growth stock, the analyst tells investors in a research note. BTIG adds that MACI growth estimates appear low for FY24 in the face of an arthroscopic launch and strong key performance indicators while also noting the modest upside that is likely to come from the NexoBrid launch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VCEL:
- Tesla, Boeing downgraded: Wall Street’s top analyst calls
- Vericel upgraded to Buy from Hold at Truist
- Vericel price target raised to $42.40 from $40 at Ladenburg
- Vericel price target raised to $46 from $44.50 at H.C. Wainwright
- Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
